Get to know our clinical trials
Ensayo clínico de fase III para evaluar la seguridad y la eficacia de Efruxifermin en sujetos con esteatohepatitis no alcohólica (EHNA) no cirrótica y fibrosis.
THE PRIMARY OBJECTIVE IN THIS STUDY IS TO EVALUATE THE EFFECT OF EFX COMPARED TO PLACEBO IN ACHIEVING RESOLUTION OF NASH AND REGRESSION OF FIBROSIS IN SUBJECTS WITH STAGE 2 OR 3 FIBROSIS AT WEEK 52
Status
In recruitment
headquarters
Madrid
Technical Summary
- PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF EFRUXIFERMIN IN SUBJECTS WITH NON-CIRRHOTIC NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND FIBROSIS
- Code EudraCT: 2023-505141-48-00
- Protocol number: AK-US-001-0105
- Promoter: Akero Therapeutics, Inc
- Molecule/Drug: Efruxifermin
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.